Annual Cash & Cash Equivalents
$142.82 M
-$1.60 M-1.11%
December 31, 2023
Summary
- As of February 7, 2025, ALDX annual cash & cash equivalents is $142.82 million, with the most recent change of -$1.60 million (-1.11%) on December 31, 2023.
- During the last 3 years, ALDX annual cash & cash equivalents has risen by +$64.96 million (+83.44%).
- ALDX annual cash & cash equivalents is now -37.85% below its all-time high of $229.79 million, reached on December 31, 2021.
Performance
ALDX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$68.12 M
-$2.91 M-4.10%
September 30, 2024
Summary
- As of February 7, 2025, ALDX quarterly cash and cash equivalents is $68.12 million, with the most recent change of -$2.91 million (-4.10%) on September 30, 2024.
- Over the past year, ALDX quarterly cash and cash equivalents has dropped by -$75.21 million (-52.47%).
- ALDX quarterly cash and cash equivalents is now -72.72% below its all-time high of $249.74 million, reached on June 30, 2021.
Performance
ALDX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALDX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.1% | -52.5% |
| 3 y3 years | +83.4% | -71.8% |
| 5 y5 years | +201.6% | +32.0% |
ALDX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -37.9% | at low | -70.4% | at low |
| 5 y | 5-year | -37.9% | +221.5% | -72.7% | +76.7% |
| alltime | all time | -37.9% | >+9999.0% | -72.7% | +5467.2% |
Aldeyra Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $68.12 M(-4.1%) |
| Jun 2024 | - | $71.03 M(-30.7%) |
| Mar 2024 | - | $102.49 M(-28.2%) |
| Dec 2023 | $142.82 M(-1.1%) | $142.82 M(-0.4%) |
| Sep 2023 | - | $143.33 M(-5.5%) |
| Jun 2023 | - | $151.68 M(-8.1%) |
| Mar 2023 | - | $165.03 M(+14.3%) |
| Dec 2022 | $144.42 M(-37.2%) | $144.42 M(+12.3%) |
| Sep 2022 | - | $128.65 M(+6.3%) |
| Jun 2022 | - | $121.01 M(-23.8%) |
| Mar 2022 | - | $158.91 M(-30.8%) |
| Dec 2021 | $229.79 M(+195.1%) | $229.79 M(-4.8%) |
| Sep 2021 | - | $241.37 M(-3.4%) |
| Jun 2021 | - | $249.74 M(+80.4%) |
| Mar 2021 | - | $138.44 M(+77.8%) |
| Dec 2020 | $77.86 M(+75.3%) | $77.86 M(-9.7%) |
| Sep 2020 | - | $86.18 M(+42.0%) |
| Jun 2020 | - | $60.69 M(+57.5%) |
| Mar 2020 | - | $38.54 M(-13.2%) |
| Dec 2019 | $44.43 M(-6.2%) | $44.43 M(-13.9%) |
| Sep 2019 | - | $51.60 M(+31.0%) |
| Jun 2019 | - | $39.40 M(-11.1%) |
| Mar 2019 | - | $44.30 M(-6.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $47.36 M(+136.5%) | $47.36 M(+163.0%) |
| Sep 2018 | - | $18.01 M(-26.8%) |
| Jun 2018 | - | $24.61 M(+17.4%) |
| Mar 2018 | - | $20.96 M(+4.7%) |
| Dec 2017 | $20.02 M(+66.7%) | $20.02 M(-39.5%) |
| Sep 2017 | - | $33.10 M(+126.6%) |
| Jun 2017 | - | $14.61 M(-24.3%) |
| Mar 2017 | - | $19.30 M(+60.7%) |
| Dec 2016 | $12.02 M(-18.0%) | $12.02 M(-17.5%) |
| Sep 2016 | - | $14.57 M(-17.3%) |
| Jun 2016 | - | $17.61 M(+73.5%) |
| Mar 2016 | - | $10.15 M(-30.7%) |
| Dec 2015 | $14.65 M(+71.8%) | $14.65 M(-52.2%) |
| Sep 2015 | - | $30.62 M(-8.8%) |
| Jun 2015 | - | $33.57 M(+113.5%) |
| Mar 2015 | - | $15.72 M(+84.4%) |
| Dec 2014 | $8.53 M(+161.4%) | $8.53 M(-15.9%) |
| Sep 2014 | - | $10.14 M(-12.1%) |
| Jun 2014 | - | $11.54 M(+437.6%) |
| Mar 2014 | - | $2.15 M(-34.2%) |
| Dec 2013 | $3.26 M(+166.6%) | $3.26 M(+18.0%) |
| Sep 2013 | - | $2.76 M(+125.9%) |
| Dec 2012 | $1.22 M(+387.5%) | $1.22 M |
| Dec 2011 | $251.00 K | - |
FAQ
- What is Aldeyra Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual cash & cash equivalents year-on-year change?
- What is Aldeyra Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Aldeyra Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ALDX is $142.82 M
What is the all time high annual cash & cash equivalents for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual cash & cash equivalents is $229.79 M
What is Aldeyra Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ALDX annual cash & cash equivalents has changed by -$1.60 M (-1.11%)
What is Aldeyra Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ALDX is $68.12 M
What is the all time high quarterly cash and cash equivalents for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly cash and cash equivalents is $249.74 M
What is Aldeyra Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ALDX quarterly cash and cash equivalents has changed by -$75.21 M (-52.47%)